Progressive Pulmonary Fibrosis (PPF) Treatment Market Snapshot (2023 to 2033)

The global progressive pulmonary fibrosis (PPF) Treatment market is expected to reach at US$ 3.72 Million in 2023 and is projected to exhibit a CAGR of 7.5% from 2023 to 2033. Several experimental cancer drugs show promise in treating idiopathic pulmonary fibrosis as a potential treatment in the future. Also, key players are increasingly focusing on research and development activity, which will create lucrative growth opportunities in the progressive pulmonary fibrosis (PPF) treatment market.

As the field of image analysis and processing advances, machine learning applications based on deep learning provide new possibilities for the use of radio mics and deep learning in image analysis. It is imperative to develop optimized algorithms in collaboration with appropriate predictors of disease outcomes and to validate radiological biomarkers against those predictors.

In randomized clinical trials, antifibrotic drugs, either nintedanib or pirfenidone, slow the progression of progressive ILD associated with IPF or progressive non-IPF ILD. The clinical management of this subgroup of patients in its current state is beginning to see a new era that offers the perfect opportunity to explore still unexplored territories within the industry.

Data Points Key Statistics
Estimated Base Year Value (2022) US$ 3.5 Million
Expected Market Value (2023) US$ 3.72 Million
Anticipated Forecast Value (2033) US$ 7.7 Million
Projected Growth Rate (2023 to 2033) 7.5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Progressive Pulmonary Fibrosis (PPF) Treatment Demand Analysis vs. Forecast 2023 to 2033

According to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6.3%. Current treatments can prolong the life of pulmonary fibrosis patients by nearly two or five years. Many researchers are currently working to discover the cause and potential treatments for pulmonary fibrosis in developed countries. Innovative therapeutic pathways for pulmonary fibrosis are currently being developed by academic institutions, pharmaceutical firms, and biopharmaceutical companies.

A rise in the number of patients with progressive pulmonary fibrosis (PPF) and the awareness surrounding its treatment is also expected to spur the development of more PPF-related pharmaceutical drugs. The progressive pulmonary fibrosis (PPF) treatment market is expected to grow at a moderate rate due to the complicated reimbursement associated with multiple patent expirations. Researchers around the world are exploring ways to treat the side effects of PPF treatments.

A new study has shown that saracatinib may be effective in treating idiopathic pulmonary fibrosis (IPF). According to a study published in the American Journal of Respiratory and Critical Care Medicine, Saracatinib reduced tissue scarring in preclinical models of IPF similarly to two drugs in clinical trials. Researchers from National Jewish Health, Mount Sinai Ichan School of Medicine, Yale School of Medicine, and AstraZeneca investigated the effectiveness of oral therapy treatments using a novel computational approach. The global demand for progressive pulmonary fibrosis (PPF) treatment is projected to increase at a CAGR of 7.5% during the forecast period between 2023 and 2033, reaching a total of US$ 7.7 Million in 2033.

What Factors are Driving Global Sales of Progressive Pulmonary Fibrosis (PPF) Treatment?

Drug Approvals and New Therapies are Expected to Grow the Market

Manufacturers of pulmonary fibrosis drugs are focusing on building strong pipelines for future launches with better patient compliance. Novel therapies are being developed for pulmonary fibrosis by different manufacturers. According to researchers, pulmonary fibrosis treatment may be accomplished with the launch of some large molecules in the upcoming years. Various research activities and drug approval processes are being conducted by manufacturers of pulmonary fibrosis drugs in various regions to generate revenue.

Technological advances and advances in medical science have led to the development of new and innovative treatments. In addition, this has contributed to the growth of the global market for pulmonary fibrosis treatments. As a result of the high prevalence of pulmonary fibrosis, several institutions have been studying the disease to understand its causes and thus contributed to the growth of the market.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Future Growth Prospects of Progressive Pulmonary Fibrosis Treatment Market

Progression therapy for pulmonary fibrosis has promising growth prospects in the future. New hope has been provided for patients suffering from pulmonary fibrosis due to recent breakthroughs in the field. In addition, new medications are being developed, stem cells are being used, new surgical techniques are being developed, and gene therapy is being utilized.

Pneumofibrosis patients can benefit from the development of new medications. A study found that pirfenidone slowed the progression of the condition and improved the overall quality of life of patients. Additionally, biologics have been found to be effective in the treatment of pulmonary fibrosis. Among the many promising treatments for pulmonary fibrosis, stem cell therapy is one of the most promising. The stem cells in the lungs are capable of regenerating tissue, and they can be used to replace damaged tissue. By doing so, oxygenation can be improved and complications can be reduced. There have been promising results in stem cell therapy so far, even though the field is still in its infancy.

MicroRNAs are considered potential targets for treating progressive pulmonary fibrosis in the future. MiRNAs play a key role in regulating different cellular functions, making it essential to understand how they influence inflammatory events causing pulmonary fibrosis to occur. Several clinical and laboratory biomarkers are being investigated in order to form a prediction of which subgroup of patients is most likely to progress or develop lung fibrosis in order to achieve a more accurate prediction.

What are the Challenges Faced by Industry Players to Progressive Pulmonary Fibrosis (PPF) Treatment in the Market?

Insufficient Treatment Options and Associated Disorders Restrict Treatment Options

Managing pulmonary fibrosis presents a limited range of treatment options. In the past, immunosuppressive medications like corticosteroids were commonly used to treat diseases off-label. As a result, Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech introduced Ofev (nintedanib) and Esbriet (pirfenidone), two medications that revolutionized the treatment of pulmonary fibrosis worldwide.

One of the major barriers to the development of treatments for pulmonary fibrosis is the high price of drugs and low per capita spending on the treatment, as well as the inaccessibility of drugs such as Ofev and Esbriet. Poor and middle-income countries are often subject to a delayed diagnosis, which can lead to more comorbidities and complicate illness management. Over 60% of pulmonary fibrosis patients suffer from comorbidities including pulmonary hypertension.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-Wise Insights

What Makes North America the Largest Market for Progressive Pulmonary Fibrosis (PPF) Treatment?

Increasing Treatment Adoption for Progressive Pulmonary Fibrosis (PPF) with New Drug Development

Due to its well-established healthcare system and high awareness of asthma patients, North America is predicted to hold 51% of the global healthcare market by 2023. Currently, North America dominates the market for progressive pulmonary fibrosis treatment. During the forecast period of 2023 to 2033, the region will continue to be a strong contributor.

The persistently increasing number of pulmonary fibrosis patients is driving the North American market for pulmonary fibrosis treatments. Asthma is one of many respiratory diseases that are on the rise in the region at a high rate of prevalence, and those cases are on the rise at an alarming rate. With such a large number of patients in the region, it is expected that the pulmonary fibrosis treatment market will thrive in the near future. In addition, rapidly evolving healthcare infrastructure, along with a growing health awareness in North America, are driving the growth of pulmonary fibrosis treatments.

A new generation of drugs being developed and approved by the FDA in this region is expected to flourish in the market further. For instance, there are two drugs approved by the Food and Drug Administration (FDA) at the moment for treating the most common form of PF, which is known as idiopathic pulmonary fibrosis (IPF). Ofev® and Esbriet® both contain nintedanib (Ofev®). Clinical trials have shown that these drugs slow down lung scarring and fibrosis, so they're called anti-fibrotic agents. Mild, moderate, and severe forms of IPF can be treated with these drugs.

How are Progressive Pulmonary Fibrosis (PPF) Treatments Lucrative in Europe?

Progressive Pulmonary Fibrosis Treatment Demand Grows as Research and Medical Facilities Expand

With a market share of 35% during the forecast period, Europe will dominate the global progressive pulmonary fibrosis (PPF) Treatment market. Research and development activities are growing rapidly in the region, and government grants are being awarded to encourage more such studies. This is expected to lead to promising growth in the pulmonary fibrosis treatment market.

Approximately 29.2% of the European market was dominated by Germany in 2022. A growing geriatric population in Germany continues to drive adoption rates higher. A growing geriatric population, Industrial advancements, and an increase in Research and Development spending all contribute to Germany's progressive pulmonary fibrosis treatment market. Increasing age is associated with a higher risk of pulmonary-related problems that occur in the body. Increasing geriatric populations are a major factor driving demand for pulmonary fibrosis treatment.

Further growth of the market is expected to be driven by the increase in hospitals for the treatment of pulmonary fibrosis and advancements in healthcare technologies and tools. More than 150 clinics in Europe are represented by the German Medical Group. Medical services can be obtained at leading German clinics through the company.

Category-wise Insights

What is the Impact of MAPK Inhibitors on the Progression of the Pulmonary Fibrosis (PPF) Treatment Market?

An increasing Number of Cancer Patients Will Increase Growth at a Significant Rate

Based on the drug class of progressive pulmonary fibrosis (PPF) treatment the market for MAPK inhibitors is expected to grow the market. As the prevalence of cancer rises, the demand for MAPK inhibitors is expected to increase thereby boosting the growth of the market. Pharmaceutical therapeutic targets for pituitary adenomas are also increasing due to the growth in healthcare expenditures. Increasing government funding will also help improve the healthcare infrastructure, further impacting the market dynamics.

In addition to the studies that have been conducted, there has been evidence that the signaling pathway plays a significant role in various types of cancers, such as melanoma and non-small cell lung cancer. As a result, researchers are increasingly interested in targeting the MAPK signaling pathway as a potentially effective cancer treatment option. Researchers and developers have been working on developing MEK inhibitors that inhibit MAPK signaling in this sector. This will all contribute to the growth of the MAPK inhibitor market.

Are Distribution Channels Potentially Stimulating the Market for Progressive Pulmonary Fibrosis (PPF) Treatment?

Treatment of Progressive Pulmonary Fibrosis (PPF) to Gain Traction in Retail Pharmacies

Based on distribution channels, the global market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The revenue share of retail pharmacies of PPF is expected to accumulate a revenue share of 52.6% during the forecast period. 

Currently, prescription drug formulations are easily obtainable and over-the-counter drugs are available at retail pharmacies, driving the market for pulmonary fibrosis treatment. With more in-house pharmacies partnering with outer retail outlets, drug sales have grown in the market. Memberships are growing, and discounts are available for loyal customers which has added further momentum to market growth. Future retail stores that deliver drugs to homes in the locality and accept online drug orders are expected to expand.

The Start-up Ecosystem: What are Start-ups Doing to Secure Future Growth Opportunities?

Some of the start-ups in the progressive pulmonary fibrosis (PPF) treatment market include-

  • ForwoRx Therapeutics is a Canada-based firm that focuses on repurposing and reformulating approved drugs. Therapeutics are being developed by the company for the treatment of chronic diseases associated with fibrosis (progressive scarring), including IPF and PAH). A company has an Oral Dissolving Tablets (ODT) platform that releases therapeutics rapidly under the tongue by dissolving the tablets rapidly under the tongue. A platform based on ODT is also offered by the company.
  • PulmoSIM Therapeutics is a United States firm specializing in therapeutics for progressive and rare respiratory diseases. In addition to PT001, PT002 is being developed for idiopathic pulmonary fibrosis and pulmonary arterial hypertension. BIOiSIM is an artificial intelligence biosimulation platform used by the company to develop drugs.

Market Competition

Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demand. End users will benefit from the use of new products and technologies by promoting them. Strategic partnerships can be formed by companies in order to increase their production capacity.

  • Boehringer Ingelheim published Phase II information on BI 10015550, a new investigational PDE4B inhibitor. It was published in The New England Journal of Medicine (NEJM). An ATS Breaking News session on May 16 in San Francisco will also present promising 12-week results demonstrating a reduction in lung function decline in IPF patients. Globally acclaimed for its pulmonary fibrosis solutions, the company aspires to one day develop a cure for the debilitating chronic disease.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 3.72 Million
Market Value in 2033 US$ 7.7 Million
Growth Rate CAGR 7.5%
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Million and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Drug Class
  • Treatment
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • FibroGen
  • Hoffmann-La Roche Ltd
  • Pliant Therapeutics, Inc.
  • United Therapeutics Corporation
  • Galapagos
  • Novartis AG
  • Prometic Life Sciences Inc.
  • Merck & Co., Inc.
Customization Available Upon Request

Key Segments Profiled in the Progressive Pulmonary Fibrosis (PPF) Treatment Market Industry Survey?

By Treatment Type:

  • MAPK Inhibitor
  • Tyrosine Inhibitor
  • Autotaxin Inhibitors

By Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Treatment:

  • Self-Care
  • Medicines
  • Pirfenidone
    • Nintedanib
    • Others
  • Lung Transplant
  • Palliative Care

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Potential of Growth in the Market?

Through 2033, the market is anticipated to prosper at a 7.5% CAGR.

What May the Market Size be in 2033?

By 2033, the market is anticipated to be worth about US$ 7.7 million.

How Significant Is the Market Size Presently?

The market is anticipated to clock in at US$ 3.72 million in 2023.

What is the Market Share of Germany?

With 29.2% of the total market, Germany took over the Europe market.

What is the North America Share of the Market?

North America is anticipated to possess 51% of the market by 2023.

What is the Leading Distribution Channel Segment?

Based on the distribution channels, PPF's retail pharmacies acquired a revenue share of 52.6%.

Table of Content
1. Executive Summary | Progressive Pulmonary Fibrosis (PPF) Treatment Market
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. PESTLE and Porter’s Analysis
    3.6. Regulatory Landscape
        3.6.1. By Key Regions
        3.6.2. By Key Countries
    3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
        5.3.1. MAPK Inhibitors
        5.3.2. Tyrosine Inhibitors
        5.3.3. Autotaxin Inhibitors
    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
        6.3.1. Hospital Pharmacies
        6.3.2. Retail Pharmacies
        6.3.3. Online Pharmacies
    6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
    6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
        7.3.1. Self-care
        7.3.2. Medicines
            7.3.2.1. Pirfenidone
            7.3.2.2. Nintedanib
            7.3.2.3. Others
        7.3.3. Lung transplant
        7.3.4. Palliative Care
    7.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
    7.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    8.1. Introduction
    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
        8.3.1. North America
        8.3.2. Latin America
        8.3.3. Europe
        8.3.4. South Asia
        8.3.5. East Asia
        8.3.6. Oceania
        8.3.7. Middle East and Africa(MEA)
    8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        9.2.1. By Country
            9.2.1.1. USA
            9.2.1.2. Canada
        9.2.2. By Drug Class
        9.2.3. By Distribution Channel
        9.2.4. By Treatment
    9.3. Market Attractiveness Analysis
        9.3.1. By Country
        9.3.2. By Drug Class
        9.3.3. By Distribution Channel
        9.3.4. By Treatment
    9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        10.2.1. By Country
            10.2.1.1. Brazil
            10.2.1.2. Mexico
            10.2.1.3. Rest of Latin America
        10.2.2. By Drug Class
        10.2.3. By Distribution Channel
        10.2.4. By Treatment
    10.3. Market Attractiveness Analysis
        10.3.1. By Country
        10.3.2. By Drug Class
        10.3.3. By Distribution Channel
        10.3.4. By Treatment
    10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        11.2.1. By Country
            11.2.1.1. Germany
            11.2.1.2. United Kingdom
            11.2.1.3. France
            11.2.1.4. Spain
            11.2.1.5. Italy
            11.2.1.6. Rest of Europe
        11.2.2. By Drug Class
        11.2.3. By Distribution Channel
        11.2.4. By Treatment
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Drug Class
        11.3.3. By Distribution Channel
        11.3.4. By Treatment
    11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        12.2.1. By Country
            12.2.1.1. India
            12.2.1.2. Malaysia
            12.2.1.3. Singapore
            12.2.1.4. Thailand
            12.2.1.5. Rest of South Asia
        12.2.2. By Drug Class
        12.2.3. By Distribution Channel
        12.2.4. By Treatment
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Drug Class
        12.3.3. By Distribution Channel
        12.3.4. By Treatment
    12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        13.2.1. By Country
            13.2.1.1. China
            13.2.1.2. Japan
            13.2.1.3. South Korea
        13.2.2. By Drug Class
        13.2.3. By Distribution Channel
        13.2.4. By Treatment
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Drug Class
        13.3.3. By Distribution Channel
        13.3.4. By Treatment
    13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        14.2.1. By Country
            14.2.1.1. Australia
            14.2.1.2. New Zealand
        14.2.2. By Drug Class
        14.2.3. By Distribution Channel
        14.2.4. By Treatment
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Drug Class
        14.3.3. By Distribution Channel
        14.3.4. By Treatment
    14.4. Key Takeaways
15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        15.2.1. By Country
            15.2.1.1. GCC Countries
            15.2.1.2. South Africa
            15.2.1.3. Israel
            15.2.1.4. Rest of Middle East and Africa(MEA)
        15.2.2. By Drug Class
        15.2.3. By Distribution Channel
        15.2.4. By Treatment
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Drug Class
        15.3.3. By Distribution Channel
        15.3.4. By Treatment
    15.4. Key Takeaways
16. Key Countries Market Analysis
    16.1. USA
        16.1.1. Pricing Analysis
        16.1.2. Market Share Analysis, 2022
            16.1.2.1. By Drug Class
            16.1.2.2. By Distribution Channel
            16.1.2.3. By Treatment
    16.2. Canada
        16.2.1. Pricing Analysis
        16.2.2. Market Share Analysis, 2022
            16.2.2.1. By Drug Class
            16.2.2.2. By Distribution Channel
            16.2.2.3. By Treatment
    16.3. Brazil
        16.3.1. Pricing Analysis
        16.3.2. Market Share Analysis, 2022
            16.3.2.1. By Drug Class
            16.3.2.2. By Distribution Channel
            16.3.2.3. By Treatment
    16.4. Mexico
        16.4.1. Pricing Analysis
        16.4.2. Market Share Analysis, 2022
            16.4.2.1. By Drug Class
            16.4.2.2. By Distribution Channel
            16.4.2.3. By Treatment
    16.5. Germany
        16.5.1. Pricing Analysis
        16.5.2. Market Share Analysis, 2022
            16.5.2.1. By Drug Class
            16.5.2.2. By Distribution Channel
            16.5.2.3. By Treatment
    16.6. United Kingdom
        16.6.1. Pricing Analysis
        16.6.2. Market Share Analysis, 2022
            16.6.2.1. By Drug Class
            16.6.2.2. By Distribution Channel
            16.6.2.3. By Treatment
    16.7. France
        16.7.1. Pricing Analysis
        16.7.2. Market Share Analysis, 2022
            16.7.2.1. By Drug Class
            16.7.2.2. By Distribution Channel
            16.7.2.3. By Treatment
    16.8. Spain
        16.8.1. Pricing Analysis
        16.8.2. Market Share Analysis, 2022
            16.8.2.1. By Drug Class
            16.8.2.2. By Distribution Channel
            16.8.2.3. By Treatment
    16.9. Italy
        16.9.1. Pricing Analysis
        16.9.2. Market Share Analysis, 2022
            16.9.2.1. By Drug Class
            16.9.2.2. By Distribution Channel
            16.9.2.3. By Treatment
    16.10. India
        16.10.1. Pricing Analysis
        16.10.2. Market Share Analysis, 2022
            16.10.2.1. By Drug Class
            16.10.2.2. By Distribution Channel
            16.10.2.3. By Treatment
    16.11. Malaysia
        16.11.1. Pricing Analysis
        16.11.2. Market Share Analysis, 2022
            16.11.2.1. By Drug Class
            16.11.2.2. By Distribution Channel
            16.11.2.3. By Treatment
    16.12. Singapore
        16.12.1. Pricing Analysis
        16.12.2. Market Share Analysis, 2022
            16.12.2.1. By Drug Class
            16.12.2.2. By Distribution Channel
            16.12.2.3. By Treatment
    16.13. Thailand
        16.13.1. Pricing Analysis
        16.13.2. Market Share Analysis, 2022
            16.13.2.1. By Drug Class
            16.13.2.2. By Distribution Channel
            16.13.2.3. By Treatment
    16.14. China
        16.14.1. Pricing Analysis
        16.14.2. Market Share Analysis, 2022
            16.14.2.1. By Drug Class
            16.14.2.2. By Distribution Channel
            16.14.2.3. By Treatment
    16.15. Japan
        16.15.1. Pricing Analysis
        16.15.2. Market Share Analysis, 2022
            16.15.2.1. By Drug Class
            16.15.2.2. By Distribution Channel
            16.15.2.3. By Treatment
    16.16. South Korea
        16.16.1. Pricing Analysis
        16.16.2. Market Share Analysis, 2022
            16.16.2.1. By Drug Class
            16.16.2.2. By Distribution Channel
            16.16.2.3. By Treatment
    16.17. Australia
        16.17.1. Pricing Analysis
        16.17.2. Market Share Analysis, 2022
            16.17.2.1. By Drug Class
            16.17.2.2. By Distribution Channel
            16.17.2.3. By Treatment
    16.18. New Zealand
        16.18.1. Pricing Analysis
        16.18.2. Market Share Analysis, 2022
            16.18.2.1. By Drug Class
            16.18.2.2. By Distribution Channel
            16.18.2.3. By Treatment
    16.19. GCC Countries
        16.19.1. Pricing Analysis
        16.19.2. Market Share Analysis, 2022
            16.19.2.1. By Drug Class
            16.19.2.2. By Distribution Channel
            16.19.2.3. By Treatment
    16.20. South Africa
        16.20.1. Pricing Analysis
        16.20.2. Market Share Analysis, 2022
            16.20.2.1. By Drug Class
            16.20.2.2. By Distribution Channel
            16.20.2.3. By Treatment
    16.21. Israel  
        16.21.1. Pricing Analysis
        16.21.2. Market Share Analysis, 2022
            16.21.2.1. By Drug Class
            16.21.2.2. By Distribution Channel
            16.21.2.3. By Treatment
17. Market Structure Analysis
    17.1. Competition Dashboard
    17.2. Competition Benchmarking
    17.3. Market Share Analysis of Top Players
        17.3.1. By Regional
        17.3.2. By Drug Class
        17.3.3. By Distribution Channel
        17.3.4. By Treatment
18. Competition Analysis
    18.1. Competition Deep Dive
        18.1.1. Boehringer Ingelheim
            18.1.1.1. Overview
            18.1.1.2. Product Portfolio
            18.1.1.3. Profitability by Market Segments
            18.1.1.4. Sales Footprint
            18.1.1.5. Strategy Overview
                18.1.1.5.1. Marketing Strategy
        18.1.2. Bristol-Myers Squibb
            18.1.2.1. Overview
            18.1.2.2. Product Portfolio
            18.1.2.3. Profitability by Market Segments
            18.1.2.4. Sales Footprint
            18.1.2.5. Strategy Overview
                18.1.2.5.1. Marketing Strategy
        18.1.3. FibroGen
            18.1.3.1. Overview
            18.1.3.2. Product Portfolio
            18.1.3.3. Profitability by Market Segments
            18.1.3.4. Sales Footprint
            18.1.3.5. Strategy Overview
                18.1.3.5.1. Marketing Strategy
        18.1.4. Hoffmann-La Roche Ltd
            18.1.4.1. Overview
            18.1.4.2. Product Portfolio
            18.1.4.3. Profitability by Market Segments
            18.1.4.4. Sales Footprint
            18.1.4.5. Strategy Overview
                18.1.4.5.1. Marketing Strategy
        18.1.5. Pliant Therapeutics, Inc.
            18.1.5.1. Overview
            18.1.5.2. Product Portfolio
            18.1.5.3. Profitability by Market Segments
            18.1.5.4. Sales Footprint
            18.1.5.5. Strategy Overview
                18.1.5.5.1. Marketing Strategy
        18.1.6. United Therapeutics Corporation
            18.1.6.1. Overview
            18.1.6.2. Product Portfolio
            18.1.6.3. Profitability by Market Segments
            18.1.6.4. Sales Footprint
            18.1.6.5. Strategy Overview
                18.1.6.5.1. Marketing Strategy
        18.1.7. Galapagos
            18.1.7.1. Overview
            18.1.7.2. Product Portfolio
            18.1.7.3. Profitability by Market Segments
            18.1.7.4. Sales Footprint
            18.1.7.5. Strategy Overview
                18.1.7.5.1. Marketing Strategy
        18.1.8. Novartis AG
            18.1.8.1. Overview
            18.1.8.2. Product Portfolio
            18.1.8.3. Profitability by Market Segments
            18.1.8.4. Sales Footprint
            18.1.8.5. Strategy Overview
                18.1.8.5.1. Marketing Strategy
        18.1.9. Prometic Life Sciences Inc.
            18.1.9.1. Overview
            18.1.9.2. Product Portfolio
            18.1.9.3. Profitability by Market Segments
            18.1.9.4. Sales Footprint
            18.1.9.5. Strategy Overview
                18.1.9.5.1. Marketing Strategy
        18.1.10. Merck & Co., Inc.
            18.1.10.1. Overview
            18.1.10.2. Product Portfolio
            18.1.10.3. Profitability by Market Segments
            18.1.10.4. Sales Footprint
            18.1.10.5. Strategy Overview
                18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Recommendations

Healthcare

Bronchopulmonary Dysplasia Treatment Market

July 2023

REP-GB-4389

313 pages

Healthcare

Cystic Fibrosis Therapeutics Market

December 2022

REP-GB-16252

299 pages

Healthcare

Chronic Obstructive Pulmonary Disease (COPD) Market

December 2022

REP-GB-16215

276 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Progressive Pulmonary Fibrosis (PPF) Treatment Market

Schedule a Call